Guardant Health Inc (GH)
Guardant Health, Inc. is a precision oncology company listed on the NASDAQ under the ticker GH. The company develops blood and tissue-based tests and related data sets for use in the United States and international markets. Its menu includes Guardant360 CDx and Guardant360 Liquid for tumor mutation profiling and biomarker detection, Guardant Reveal for molecular cancer detection using circulating tumor DNA, and Guardant360 Tissue for genomic, transcriptomic, and epigenomic profiling of tumor tissue. Guardant Health also offers Shield for colorectal cancer screening in adults, along with GuardantINFINITY, GuardantOMNI, GuardantINFORM, and GuardantConnect to support research, therapy development, and clinical connectivity. The company further provides its Smart Platform and a range of development and support services, including companion diagnostic development, regulatory support, clinical study operations, testing development, licensing, and kit fulfillment. Guardant Health was incorporated in 2011 and is headquartered in Palo Alto, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GH
|
$107.12
|
-29.4% Downside
|
Overvalued
|
$171.08
|
12.8% Upside
|
Fair
|
Good
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-46.5x
|
-111.2x
|
18.6x
|
19.634 B
|
20.732 B
|
8.0%
|
96.4%
|
3.7
|
—
|
54.7%
|
